Pharmacological Modulation of Schizophrenia-Related Behaviors

(+)-MK-801 (130–17,381), Memantine (131–18,313), and Haloperidol (084–04261) were purchased from Fujifilm Wako Pure Chemical Corporation (Osaka, Japan) and Betahistine (B1424) was purchased from Tokyo Chemical Industry Co., Ltd. (Tokyo, Japan). All reagents were diluted in saline and administered intraperitoneally. (+)-MK-801 was diluted to a concentration of 0.1 mg/mL and administered at a dose of 0.2 mg/kg. This dose was selected based on previous studies demonstrating a schizophrenia-related deficient effect of MK-801 at 0.2 mg/kg in mice [43 (link)–45 (link)]. Memantine was diluted at a concentration of 10 mg/mL and administered at a dose of 20 mg/kg. This dose was selected based on previous studies demonstrating a hyperlocomotive effect of memantine at 20 mg/kg in mice [35 (link)]. Haloperidol was dissolved in saline with a minimal amount of acetic acid [46 (link)] and administered at a dose of 2 mg/kg, whereas, betahistine was diluted at a concentration of 10 mg/mL and administered at a dose of 10 mg/kg [35 (link)]. The same amount of acetic acid was added to the vehicle for control animals.